Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023
Ethnobridging study initiated in Japanese individuals and formulation bridging study planned to evaluate tablet formulation in preparation for global Phase 2b study of GSBR-1290 in 2024
SAN FRANCISCO and SHANGHAI, China, May 25, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus (T2DM) who are overweight or obese. The Company has also initiated an ethnobridging study of GSBR-1290 in Japanese individuals and is planning to initiate an additional formulation bridging study to evaluate a tablet formulation of GSBR-1290 before the end of the year, both in preparation for the planned global Phase 2b study in 2024.
“The initiation of the Phase 2a clinical trial marks a major milestone in our mission to bring an effective and convenient oral therapy to patients living with type 2 diabetes and obesity,” said Mark Bach, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics. “We are excited to advance GSBR-1290, an orally available small molecule GLP1 agonist, into the next stage of clinical development. This is the first program in our GLP-1 incretin franchise, and evaluating GSBR-1290 in Japanese patients demonstrates our commitment to rapidly developing this treatment globally.”
About the Phase GSBR-1290 development program
Topline data from the Phase 2a study as well as the Phase1b MAD study are expected to be announced in the latter half of the fourth quarter of 2023.
In addition, the Company has initiated a Phase 1 ethobridging study to evaluate the safety, tolerability, and PK of single and multiple doses of GSBR-1290 in Japanese patients. The study will include 12 healthy adult Japanese participants randomized 3:1 to GSBR-1290 or placebo, and six non-Japanese participants who will all receive GSBR-1290. All participants will receive GSBR-1290 once daily (QD) for seven days at each dose, with a total of four doses titrated up over a 4-week period). Successful completion of this study is intended to enable inclusion of Japanese patients in the planned global Phase 2b study in 2024.
The Company is also planning a separate formulation bridging pharmacokinetic study to support the planned transition from capsules to tablets. Pending supportive data from this bridging study, the tablet formulation would be used in future GSBR-1290 studies starting with the planned Phase 2b study.
About Structure Therapeutics
Forward Looking Statements
Special Panel Discussion and Reception: Single Pane of Glass - Managing the Evolution to E-SIM
GenAI and the Impact on the Enterprise
CCaaS and MSPs: The Perfect Partnership